Compare IDEXX Laboratories, Inc. (IDXX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs TeraWulf Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while TeraWulf Inc trades at $17.2 (market cap $8.35B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.5× TeraWulf Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | WULF | |
|---|---|---|
Market Cap | $46.22B | $8.35B |
Sector | Health | Technology |
52-Week High | $766.68 | $28.98 |
52-Week Low | $526.44 | $5.24 |
Enterprise Value | $47.12B | $10.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
WULF trades at $17.19, up 6.11% today amid a broader neocloud sector rally. The stock shows bearish technical signals with negative earnings trends, posting significant losses in recent quarters. Despite strong analyst consensus (14 buy ratings, 0 hold/sell), fundamental metrics reveal challenges with a P/S of 43.81, P/B of 56.71, and deeply negative profit margins. Recent news highlights the company's pivot to high-performance computing with a major Anthropic deal and 102 MW of operational capacity.
The outlook remains speculative with high execution risks and substantial capital requirements. While analyst price targets average $38.00 (121% upside potential), investors face volatility from ongoing losses, construction cost pressures, and regulatory exposure to New York's data-center moratorium. The stock's performance will depend on successful HPC expansion and profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
